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Drug-eluting stents (DES) have been associated with late-stent thrombosis and subacute-stent failure. The 
thrombosis related mortality rate urgently requires improved therapeutic options. These therapies are tasked to 
reduce neointimal hyperplasia whilst encouraging endothelialisation. This study assessed the metabolic activity of 
a number of different drugs with application in DESs.  
Curcumin, ferulic acid, exendin-4, magnolol, everolimus and paclitaxel of varying concentrations (1-100µM, 0.5-
500µM, 1-50nM, 3.75µM-375µM, 10-100µM, 1-100µM, respectively) were assessed upon dosing porcine coronary 
artery endothelial cells (PCAEC) and smooth muscle cells (PCASMC) and human coronary artery smooth muscle 
cells (HCASMCs) and umbilical vein endothelial cells (HUVECs). A metabolic activity assay (WST-8) was 
independently conducted upon 24, 48, 72 and 144h of treatment and was compared to untreated cells. Samples 
were studied in triplicates.  
The metabolic activity indicated that curcumin and magnolol induced cytotoxic effects/reduced metabolic activity 
on ECs at the majority of concentrations. Curcumin at 1, 5 and 10µM caused a slight increase in metabolic activity 
on both SMCs. 5µM of ferulic acid boosted PCAEC metabolic activity and maintained SMC activity. Exendin-4 
showed significant increase in metabolic activity of PCAECs and HUVECs at 144h, suggesting time dependant 
dosage. It was noted that ECs were more sensitive to commercially-used anti-proliferative controls (paclitaxel and 
everolimus).   
This assessment demonstrated an initial judgement and promising strategy to identify ideal drugs for DESs. Certain 
concentrations for ferulic Acid and exendin-4 have shown ideal metabolic activities and will be subjected to further 
assessment, including their effect on cell metabolic activity and phenotype under dynamic flow conditions.  
